Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

NEKTAR THERAPEUTICS ($NKTR) posted quarterly earnings results on Wednesday, March 12th. The company reported earnings of $0.15 per share, beating estimates of -$0.17 ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...

For the quarter ended December 2024, Nektar Therapeutics (NKTR) reported revenue of $29.18 million, up 22.1% over the same period last year. EPS came in at $0.15, compared to -$0.22 in the year ...

Nektar Therapeutics (NKTR) reported $29.18 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 22.1%. EPS of -$0.15 for the same period compares to -$ ...

(RTTNews) - Below are the earnings highlights for Nektar Therapeutics (NKTR): Earnings ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Jonathan Zalevsky, the Chief R&D Officer of $NKTR, sold 10,300 shares of the company on 02-19-2025 for an estimated $10,403. We received data on the trade from a ...

SAN FRANCISCO, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday ...